Immunocore
September 18, 2017
Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announced an investment from the Bill & Melinda Gates Foundation to support the development of Immunocore’s soluble TCR-based therapeutics for infectious diseases.
The Bill & Melinda Gates Foundation will invest up to $40 million in Immunocore to support development of Immunocore’s ImmTAV (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB (Immune mobilising monoclonal TCRs Against Bacteria) therapeutics for infectious diseases that pose a global health challenge.